Volume 22 Issue 2
Feb.  2024
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2024  >  22(2): 206-208
XU Hongbo, ZHANG Yajun, HUANG Zhifei, ZHAO Hongyu, LIU Zixuan, GAO Bo, CAI Feng, SONG Shilong, HE Zelai, JIANG Hao. Analysis of the short-term efficacy and side effects of concurrent chemoradiotherapy combined with nimotuzumab in patients with locally advanced nasopharyngeal carcinoma[J]. Chinese Journal of General Practice, 2024, 22(2): 206-208. doi: 10.16766/j.cnki.issn.1674-4152.003366
Citation: XU Hongbo, ZHANG Yajun, HUANG Zhifei, ZHAO Hongyu, LIU Zixuan, GAO Bo, CAI Feng, SONG Shilong, HE Zelai, JIANG Hao. Analysis of the short-term efficacy and side effects of concurrent chemoradiotherapy combined with nimotuzumab in patients with locally advanced nasopharyngeal carcinoma[J]. Chinese Journal of General Practice, 2024, 22(2): 206-208. doi: 10.16766/j.cnki.issn.1674-4152.003366
shu

Analysis of the short-term efficacy and side effects of concurrent chemoradiotherapy combined with nimotuzumab in patients with locally advanced nasopharyngeal carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.003366

  • Department of Radiotherapy, the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 2020b07030008

 KJ2021A0781

  • Received Date: 2023-09-11
    Available Online: 2024-03-27
    Abstract
  •   Objective  Nasopharyngeal carcinoma has unique anatomical and biological characteristics, and radiotherapy or concurrent chemoradiotherapy is an effective treatment mode. However, many patients with locally advanced nasopharyngeal carcinoma still experience local recurrence or distant metastasis. Therefore, targeted therapy provides an additional option for nasopharyngeal carcinoma patients. This article aims to evaluate the short-term efficacy and toxicity of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma patients, and further analyze the impact of intensity-modulated radiation therapy (IMRT) and helical tomotherapy (TOMO) on patiens' side effects.  Methods  A retrospective analysis was conducted on the clinical data of 88 patients with locally advanced nasopharyngeal carcinoma admitted to the Radiotherapy Department of the First Affiliated Hospital of Bengbu Medical University from December 2020 to June 2023. The treatment group consisted of 44 patients who received concurrent chemoradiotherapy with nimotuzumab targeted therapy, while the control group consisted of 44 patients who only received concurrent chemoradiotherapy. The short-term treatment efficacy, toxic side effects, and the impact of different radiotherapy methods on side effects were compared and analyzed.  Results  In the treatment group, the overall response rate (ORR) for the nasopharyngeal region and cervical lymph nodes were 97.8% (43/44) and 93.2% (41/44) respectively, while in the control group, the ORR were 81.8%(36/44) and 81.8% (36/44) respectively. The incidence of mucositis was higher in the treatment group compared to the control group: 84.1%(37/44) compared to 63.6%(28/44), P<0.05. Further analysis showed that the incidence of mucositis was lower in patients receiving TOMO in both the treatment and control groups than in the IMRT, but the difference was not statistically significant (P>0.05).  Conclusion  For patients with locally advanced nasopharyngeal carcinoma, concurrent chemoradiotherapy with nimotuzumab provides better short-term efficacy, while patients receiving TOMO have a decreasing trend in mucosal reactions.

     

    • FullText(HTML)
  • loading
    • References(18)
  • [1]
    CHEN Y P, CHAN A T C, LE Q T, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192): 64-80. doi: 10.1016/S0140-6736(19)30956-0
    [2]
    XIA W X, LV X, LIANG H, et al. A randomized controlled trial comparing two different schedules for cisplatin treatment in patients with locoregionally advanced nasopharyngeal cancer[J]. Clin Cancer Res, 2021, 27(15): 4186-4194. doi: 10.1158/1078-0432.CCR-20-4532
    [3]
    YIN Y X, ZHOU Z Y, LI Z R, et al. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study[J]. Radiat Oncol, 2022, 17(1): 135. doi: 10.1186/s13014-022-02104-4
    [4]
    BLANCHARD P, LEE A W M, CARMEL A, et al. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): an update on 26 trials and 7080 patients[J]. Clin Transl Radiat Oncol, 2022, 32: 59-68.
    [5]
    LIU Y, YANG L, ZHANG S, et al. The efficacy and safety of concurrent chemoradiotherapy with induction chemotherapy vs. concurrent chemoradiotherapy alone for locally advanced nasopharyngeal carcinoma: a systematic-review and meta-analysis[J]. Transl Cancer Res, 2022, 11(5): 1207-1218. doi: 10.21037/tcr-22-604
    [6]
    LIANG R B, YANG L, ZHU X D. Nimotuzumab, an Anti-EGFR monoclonal antibody, in the treatment of nasopharyngeal carcinoma[J]. Cancer Control, 2021, 28: 1073274821989301. DOI: 10.1177/1073274821989301.
    [7]
    COX J D, STETZ J, PAJAK T F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1341-1346. doi: 10.1016/0360-3016(95)00060-C
    [8]
    FREITES-MARTINEZ A, SANTANA N, ARIAS-SANTIAGO S, et al. Using the common terminology criteria for adverse events (CTCAE-Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92. doi: 10.1016/j.ad.2019.05.009
    [9]
    NI X L, ZHANG J Q, ZHU D, et al. Cetuximab or nimotuzumab in combination with chemotherapy for treating recurrent/metastatic nasopharyngeal carcinoma: a meta-analysis and systemic review[J]. Oncol Lett, 2023, 25(5): 204. doi: 10.3892/ol.2023.13790
    [10]
    LUAN W H, YUAN H Z, HOU W, et al. Improvement and prognosis analysis of nimotuzumab combined with TP regimen induction chemotherapy and sequential concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma[J]. Am J Transl Res, 2022, 14(8): 5630-5640.
    [11]
    WANG L L, ZHUANG H Z, XU X Y, et al. Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma[J]. Front Oncol, 2023, 13: 1129649. DOI: 10.3389/fonc.2023.1129649.
    [12]
    PENG H, TANG L L, LIU X, et al. Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma[J]. Cancer Sci, 2018, 109(5): 1609-1616. doi: 10.1111/cas.13589
    [13]
    营巧玲, 何泽来, 郭术楠, 等. 结直肠癌寡转移三维适形调强放疗的临床评价[J]. 中华全科医学, 2019, 17(11) : 1802-1805. doi: 10.16766/j.cnki.issn.1674-4152.001059

    YING Q L, HE Z L, GUO S N, et al. Clinical evaluation of three-dimensional conformal intensity modulated radiotherapy for colorectal cancer oligometastases[J]. Chinese Journal of General Practice, 2019, 17(11): 1802-1805. doi: 10.16766/j.cnki.issn.1674-4152.001059
    [14]
    KUO C Y, LIU W H, CHOU Y C, et al. To optimize radiotherapeutic plans for superior tumor coverage predicts malignant glioma prognosis and normal tissue complication probability[J]. J Clin Med, 2022, 11(9): 2413. doi: 10.3390/jcm11092413
    [15]
    LI D P, WANG D D, FENG S, et al. Comparing dosimetric and cancer control outcomes after intensity-modulated radiation therapy and tomotherapy for advanced cervical cancer[J]. Oncol Lett, 2022, 24(1): 239. doi: 10.3892/ol.2022.13359
    [16]
    WANG Q L, QIN J Y, CAO R X, et al. Comparison of dosimetric benefits of three precise radiotherapy techniques in nasopharyngeal carcinoma patients using a priority-classified plan optimization model[J]. Front Oncol, 2021, 11: 646584. DOI: 10.3389/fonc.2021.646584.
    [17]
    LU S, FAN H Q, HU X Y, et al. Dosimetric comparison of helical tomotherapy, volume-modulated arc therapy, and fixed-field intensity-modulated radiation therapy in locally advanced nasopharyngeal carcinoma[J]. Front Oncol, 2021, 11: 764946. DOI: 10.3389/fonc.2021.764946.
    [18]
    LIU Z G, XU C Y, JIANG R, et al. Treatment of locally advanced nasopharyngeal carcinoma by Helical Tomotherapy: an observational, prospective analysis[J]. Transl Oncol, 2019, 12(5): 757-763. doi: 10.1016/j.tranon.2019.02.011
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (47) PDF downloads(4) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return